Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bray

Showing results (221-230 of 247) with videos related to

Pageof 25
Sort By:
Archives of Physical Medicine and Rehabilitation|May 4, 2010
Leisure time physical activity in a population-based sample of people with spinal cord injury part II: activity types, intensities, and durationsKathleen A Martin Ginis, Kelly P Arbour-Nicitopoulos, Amy E Latimer, et al.
Nature Communications|June 20, 2019
Fcmr regulates mononuclear phagocyte control of anti-tumor immunityShawn P Kubli, Larsen Vornholz, Gordon Duncan, et al.
Nature Communications|September 5, 2019
Author Correction: Fcmr regulates mononuclear phagocyte control of anti-tumor immunityShawn P Kubli, Larsen Vornholz, Gordon Duncan, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|May 22, 2012
Predictors of leisure time physical activity among people with spinal cord injuryKathleen A Martin Ginis, Kelly P Arbour-Nicitopoulos, Amy E Latimer-Cheung, et al.
Cancer Cell|March 16, 2005
DJ-1, a novel regulator of the tumor suppressor PTENRaymond H Kim, Malte Peters, YingJu Jang, et al.
British Journal of Cancer|July 16, 2019
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trialZachary W Veitch, David W Cescon, Trisha Denny, et al.
Urology|August 5, 2000
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and stagingW J Catalona, P C Southwick, K M Slawin, et al.
Blood|October 9, 1999
Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantationE C LaCasse, M R Bray, B Patterson, et al.
Investigational New Drugs|July 14, 2016
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemiaKaren W L Yee, Hsiao-Wei T Chen, David W Hedley, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancerUrsula A Matulonis, Julie Lee, Brian Lasonde, et al.
Pageof 25

Showing results (221-230 of 247) with videos related to

Sort By:
Pageof 25
Archives of Physical Medicine and Rehabilitation|May 4, 2010
Leisure time physical activity in a population-based sample of people with spinal cord injury part II: activity types, intensities, and durationsKathleen A Martin Ginis, Kelly P Arbour-Nicitopoulos, Amy E Latimer, et al.
Nature Communications|June 20, 2019
Fcmr regulates mononuclear phagocyte control of anti-tumor immunityShawn P Kubli, Larsen Vornholz, Gordon Duncan, et al.
Nature Communications|September 5, 2019
Author Correction: Fcmr regulates mononuclear phagocyte control of anti-tumor immunityShawn P Kubli, Larsen Vornholz, Gordon Duncan, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|May 22, 2012
Predictors of leisure time physical activity among people with spinal cord injuryKathleen A Martin Ginis, Kelly P Arbour-Nicitopoulos, Amy E Latimer-Cheung, et al.
Cancer Cell|March 16, 2005
DJ-1, a novel regulator of the tumor suppressor PTENRaymond H Kim, Malte Peters, YingJu Jang, et al.
British Journal of Cancer|July 16, 2019
Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trialZachary W Veitch, David W Cescon, Trisha Denny, et al.
Urology|August 5, 2000
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and stagingW J Catalona, P C Southwick, K M Slawin, et al.
Blood|October 9, 1999
Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantationE C LaCasse, M R Bray, B Patterson, et al.
Investigational New Drugs|July 14, 2016
A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemiaKaren W L Yee, Hsiao-Wei T Chen, David W Hedley, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancerUrsula A Matulonis, Julie Lee, Brian Lasonde, et al.
Pageof 25